Advanz Pharma (CXRXF) Set to Announce Earnings on Wednesday

Advanz Pharma (OTCMKTS:CXRXF) will post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Advanz Pharma to post earnings of ($0.45) per share for the quarter.

Advanz Pharma (OTCMKTS:CXRXF) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $135.64 million during the quarter. On average, analysts expect Advanz Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

OTCMKTS:CXRXF opened at $13.83 on Wednesday. The business’s 50-day simple moving average is $15.44. The firm has a market cap of $679.89 million, a PE ratio of 1.17 and a beta of 0.50. Advanz Pharma has a 1 year low of $12.72 and a 1 year high of $60.51. The company has a current ratio of 2.01, a quick ratio of 1.71 and a debt-to-equity ratio of 6.47.

Several analysts have commented on the company. Zacks Investment Research downgraded General Finance from a “buy” rating to a “hold” rating in a research note on Monday, July 15th. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd.

Advanz Pharma Company Profile

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Featured Story: What is a growth and income fund?

Earnings History for Advanz Pharma (OTCMKTS:CXRXF)

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.